4DMT reports Q1 net loss $28.7M; cash runway into H1 2026 after $129M offering

4D Molecular Therapeutics, Inc.

2023-Q1 EPS reported -$0.88 revenue$298,000

Net loss $28.7M for Q1 2023 vs $26.3M in Q1 2022; R&D expenses $22.4M.
Cash, equivalents and marketable securities $202M as of March 31, 2023; plus $129M net from May 2023 offering.
Positive interim data from 4D-150 Phase 1/2 PRISM trial for wet AMD: 100% injection-free at 36 weeks in 3E10 cohort.
Acquired worldwide rights to sCFH from Aevitas for 4D-175 (geographic atrophy) candidate.
Enrollment of Phase 2 dose expansion for 4D-150 expected to complete Q3 2023; initial data H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

4D Molecular Therapeutics, Inc. reported three months ended March 31, 2023 results: net income $28.7 million.

Period: three months ended March 31, 2023
Net income: $28.7 million
Result: reported results

Exact text from the filing

Net loss was $28.7 million for the quarter ended March 31, 2023

View on SEC.gov

Browse all earnings releases →

4D Molecular Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020699

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.